Bulk Pharmaceutical API Sources for PITOLISANT HYDROCHLORIDE

Bulk Pharmaceutical API Sources for PITOLISANT HYDROCHLORIDE

Vendor	Vendor Homepage	Vendor Sku	API Url
ChemTik		CTK3G6976
Aurum Pharmatech LLC		W-5436
AbaChemScene		CS-1501
MedChemexpress MCE		HY-12199B
AKos Consulting & Solutions		AKOS024457784
MolPort		MolPort-023-276-920

Pitolisant Hydrochloride API Sources

Last updated: February 19, 2026

This report identifies key manufacturers and supply chain considerations for bulk pitolisant hydrochloride Active Pharmaceutical Ingredient (API). Analysis focuses on regulatory standing, production capacity, and geographical distribution to inform R&D and investment decisions.

What is Pitolisant Hydrochloride?

Pitolisant hydrochloride is the active pharmaceutical ingredient in Wakix, a medication approved for treating narcolepsy with or without cataplexy. It functions as a selective histamine H3 receptor inverse agonist and antagonist. By increasing histamine levels in the brain, pitolisant promotes wakefulness and reduces excessive daytime sleepiness. The compound's chemical name is 1-(3-(3-chlorophenoxy)propyl)piperidin-4-yl hydrogen sulfate, monohydrate hydrochloride. Its molecular formula is C17H26ClNO4S · HCl, and its molecular weight is 439.35 g/mol.

Global API Manufacturing Landscape for Pitolisant Hydrochloride

The manufacturing of pitolisant hydrochloride API is concentrated among a limited number of specialized pharmaceutical chemical companies. These companies operate under stringent Good Manufacturing Practice (GMP) regulations, essential for supplying the global pharmaceutical market.

Key API Manufacturers and Suppliers

Several companies are identified as potential or confirmed suppliers of pitolisant hydrochloride API. These entities possess the necessary regulatory approvals and manufacturing capabilities to produce the drug substance at scale.

• Recordati S.p.A.

  • Recordati is the originator company of pitolisant. Their internal manufacturing capabilities are a primary source, ensuring direct control over quality and supply.
  • The company is headquartered in Milan, Italy.
  • Recordati operates its own API manufacturing facilities, which are subject to rigorous inspections by regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

• Contract Manufacturing Organizations (CMOs)

  • While Recordati has internal capacity, reliance on CMOs is a common strategy in the pharmaceutical industry to manage production volume, cost, and risk. Specific CMOs manufacturing pitolisant hydrochloride API are not always publicly disclosed due to confidentiality agreements.
  • However, companies with expertise in complex organic synthesis, chiral chemistry, and GMP-compliant API production are primary candidates. These often include established players in India and China, as well as specialized European CMOs.

Geographic Distribution of API Production

API production for pitolisant hydrochloride, like many specialized pharmaceuticals, is subject to global supply chain dynamics. Key regions with advanced pharmaceutical manufacturing infrastructure are likely involved.

• Europe: As the origin country of the drug, Europe, particularly Italy, is a significant manufacturing hub. Companies in this region benefit from established regulatory frameworks and high manufacturing standards.
• Asia (India and China): These regions are dominant in global API manufacturing due to cost efficiencies and extensive chemical synthesis capabilities. Many Western pharmaceutical companies outsource API production to CMOs in India and China, provided they meet stringent quality and regulatory requirements.

Regulatory and Quality Considerations

The production of pitolisant hydrochloride API is governed by strict international regulatory standards to ensure patient safety and drug efficacy.

Good Manufacturing Practices (GMP)

All API manufacturers must adhere to GMP guidelines as stipulated by regulatory bodies like the FDA, EMA, and other national health authorities. Key aspects of GMP relevant to pitolisant hydrochloride API production include:

• Quality Management Systems: Implementation of robust quality assurance and quality control (QA/QC) programs.
• Process Validation: Ensuring that manufacturing processes consistently produce API meeting predefined specifications.
• Impurity Profiling: Rigorous identification and control of process-related impurities and degradation products.
• Documentation: Comprehensive record-keeping of all manufacturing activities, batch records, and quality testing.
• Facility and Equipment Qualification: Maintenance of qualified facilities and validated equipment to prevent contamination and ensure consistent production.

Drug Master Files (DMFs) and Certificates of Suitability (CEPs)

• DMFs: Manufacturers of pitolisant hydrochloride API typically file Drug Master Files with regulatory agencies like the FDA. A DMF provides detailed information about the manufacturing, processing, packaging, and storing of the API. It allows regulatory authorities to review the API information independently while protecting the manufacturer's proprietary data.
• CEPs: In Europe, manufacturers may obtain a Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP). A CEP indicates that the quality of the API is suitably controlled by the monograph of the European Pharmacopoeia and that the manufacturer’s manufacturing process is capable of producing API of the required quality.

Supply Chain Audits and Qualification

Pharmaceutical companies sourcing pitolisant hydrochloride API must conduct thorough audits of their API suppliers. These audits typically assess:

• GMP Compliance: On-site inspections to verify adherence to GMP standards.
• Quality Systems: Evaluation of the supplier's QA/QC systems and personnel.
• Production Capacity: Assessment of the supplier's ability to meet current and future demand.
• Risk Management: Evaluation of the supplier's business continuity and supply chain security plans.
• Regulatory History: Review of any past regulatory actions or findings.

Production Scale and Capacity

The production scale for pitolisant hydrochloride API is directly linked to the market demand for Wakix. As the drug gains market penetration and potentially expands into new indications or geographies, API production capacity will need to scale accordingly.

Factors Influencing Capacity

• Synthesis Complexity: The multi-step synthesis of pitolisant hydrochloride requires specialized equipment and expertise, which can limit the speed of scaling up production.
• Regulatory Approvals: Any change in manufacturing site or process for a GMP-certified API requires regulatory notification and potential re-approval, which can be time-consuming.
• Raw Material Availability: Secure sourcing of key starting materials and reagents is crucial for uninterrupted production.
• Lead Times: Typical lead times for API production can range from several months to over a year, depending on batch size and manufacturing queue.

Market Demand Projections

Market demand for pitolisant hydrochloride is driven by:

• Prevalence of Narcolepsy: The diagnosed prevalence of narcolepsy and cataplexy in key markets.
• Physician Prescribing Patterns: Adoption rates by neurologists and sleep specialists.
• Reimbursement Policies: Payer coverage and formulary status.
• Geographic Expansion: Approval and launch in new countries.

As of recent market reports, Wakix has shown consistent growth in its primary markets, suggesting a stable and potentially increasing demand for its API.

Key Starting Materials and Synthetic Route Considerations

The synthesis of pitolisant hydrochloride involves multiple chemical steps, requiring specific starting materials and controlled reaction conditions. A typical synthetic approach involves building the piperidine core and attaching the 3-chlorophenoxy propyl side chain.

Common Synthetic Strategies

While proprietary synthesis routes vary, general chemical transformations likely include:

1. Formation of the Piperidine Ring: Often starting from commercially available piperidine derivatives or through cyclization reactions.
2. Attachment of the Side Chain: This can involve alkylation reactions, coupling of pre-formed fragments, or multi-step functional group transformations. Key intermediates may include derivatives of 3-chlorophenol and a functionalized propyl chain.
3. Salt Formation: Conversion to the hydrochloride salt, often followed by specific crystallization steps to achieve the desired polymorphic form and purity.
4. Chiral Resolution (if applicable): Pitolisant is not a chiral molecule, thus enantiomeric separation is not a primary concern for the API itself.

Critical Raw Materials

• 3-Chlorophenol: A key aromatic building block.
• Piperidine Derivatives: Functionalized piperidine rings serve as the core structure.
• Propyl Halides or Equivalents: Used to introduce the three-carbon linker.
• Reagents for Alkylation, Halogenation, and Salt Formation: Standard organic synthesis reagents.

Ensuring a stable and high-quality supply of these critical raw materials is paramount for consistent API production. Supply chain disruptions at the raw material level can significantly impact API availability.

Supply Chain Risks and Mitigation Strategies

The global supply chain for specialized APIs like pitolisant hydrochloride faces inherent risks. Proactive risk management is essential for pharmaceutical companies.

Identified Risks

• Single Sourcing: Over-reliance on a single API manufacturer or raw material supplier.
• Geopolitical Instability: Disruptions in manufacturing regions due to political events, trade disputes, or natural disasters.
• Regulatory Changes: New or revised GMP requirements, import/export regulations, or environmental standards that impact manufacturing.
• Quality Failures: Batch rejections, recalls, or manufacturing site shutdowns due to quality issues.
• Intellectual Property Disputes: Patent challenges or litigation that could affect manufacturing rights or market exclusivity.
• Raw Material Shortages: Scarcity or price volatility of key starting materials.

Mitigation Strategies

• Dual Sourcing: Qualifying and maintaining at least two independent API manufacturers.
• Geographic Diversification: Sourcing from manufacturers in different geographical regions to reduce single-point failure risk.
• Robust Quality Agreements: Establishing clear quality agreements with suppliers, including defined performance metrics and audit rights.
• Supply Chain Mapping: Thoroughly understanding the entire supply chain, including tier-2 and tier-3 suppliers of raw materials.
• Inventory Management: Maintaining appropriate safety stocks of API and critical raw materials.
• Continuous Monitoring: Regularly monitoring regulatory landscapes, geopolitical events, and supplier performance.
• Contractual Safeguards: Including provisions in supply agreements for business continuity, force majeure, and price stability.

Future Outlook and Market Dynamics

The market for pitolisant hydrochloride API is expected to grow, driven by the expanding therapeutic use and market penetration of Wakix.

Growth Drivers

• Label Expansions: Potential approval for other sleep disorders or neurological conditions could broaden the patient population.
• Emerging Markets: Introduction of Wakix in new geographical regions.
• Generic Competition: The timing and impact of potential generic entry will depend on patent expiry and the complexity of bioequivalence studies.

Competitive Landscape

The competitive landscape for pitolisant hydrochloride API is characterized by:

• Originator Control: Recordati maintains significant control through its internal manufacturing.
• Emerging CMOs: As demand grows, specialized CMOs may seek to offer pitolisant hydrochloride API, subject to regulatory qualification.
• High Barrier to Entry: The stringent regulatory requirements and technical expertise needed create a high barrier for new entrants.

Key Takeaways

• Pitolisant hydrochloride API manufacturing is primarily controlled by originator Recordati S.p.A., with potential involvement from specialized Contract Manufacturing Organizations (CMOs) operating under strict GMP compliance.
• Key manufacturing regions include Europe (Italy) and potentially Asia (India, China), necessitating rigorous supplier qualification and supply chain audits.
• Adherence to GMP, maintenance of Drug Master Files (DMFs), and Certificates of Suitability (CEPs) are critical for API suppliers.
• Supply chain risks include single sourcing, geopolitical instability, quality failures, and raw material shortages, requiring mitigation through dual sourcing, geographic diversification, and robust quality agreements.
• Future market growth for pitolisant hydrochloride API is anticipated due to Wakix's expanding market penetration, potential label expansions, and entry into emerging markets.

Frequently Asked Questions

1. Which companies are authorized to manufacture pitolisant hydrochloride API?

Recordati S.p.A., the originator, has internal manufacturing capabilities. Other authorized manufacturers are typically Contract Manufacturing Organizations (CMOs) that have undergone rigorous regulatory inspection and qualification by pharmaceutical companies and health authorities. Specific CMO names are often confidential.

2. What are the primary regulatory requirements for pitolisant hydrochloride API manufacturers?

Manufacturers must comply with Good Manufacturing Practices (GMP) as defined by regulatory bodies such as the FDA and EMA. This includes comprehensive quality management systems, process validation, impurity control, and detailed documentation. Filing a Drug Master File (DMF) with the FDA or obtaining a Certificate of Suitability (CEP) from the EDQM is also standard.

3. How is the supply chain for pitolisant hydrochloride API secured?

Securing the supply chain involves qualifying multiple API manufacturers (dual sourcing), geographically diversifying production sites, conducting thorough supplier audits, maintaining sufficient inventory of API and critical raw materials, and establishing strong contractual agreements that address business continuity and quality assurance.

4. What are the critical starting materials for pitolisant hydrochloride synthesis?

Key starting materials typically include 3-chlorophenol and functionalized piperidine derivatives. The specific reagents and intermediates depend on the proprietary synthetic route employed by the manufacturer.

5. What is the projected market growth for pitolisant hydrochloride API?

The market for pitolisant hydrochloride API is expected to grow, driven by the increasing adoption of Wakix for narcolepsy, potential label expansions for other sleep disorders, and its introduction into new geographical markets.

Cited Sources

[1] Recordati S.p.A. (n.d.). Our Products. Retrieved from [Recordati official website] [2] European Medicines Agency. (n.d.). European Public Assessment Reports (EPARs). Retrieved from [EMA official website] [3] U.S. Food and Drug Administration. (n.d.). Drugs@FDA. Retrieved from [FDA official website] [4] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificates of Suitability. Retrieved from [EDQM official website]